SEC Form 4 · accession 0001886794-26-000008
Vaxcyte, Inc. · PCVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harpreet S. Dhaliwal
Officer — Chief Technical Ops Officer
Period of report
Aug 5, 2026
Accepted (ET)
Aug 5, 2026 · 7:01 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001649094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 5, 2026 | M | 17,000 | $24.79 | A | 93,756 | D | |
| Common StockF3 | Aug 5, 2026 | S | 17,000 | $55.004 | D | 76,756 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $24.79 | Aug 5, 2026 | M | 17,000 | D | — | Mar 2, 2032 | Common Stock | 17,000 | 28,000 | D |
Explanation of responses
- F1Includes 780 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026.
- F2The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 6, 2026.
- F3The price reported is a weighted-average price. The shares were sold at prices ranging from $55.00 to $55.255. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Stock Option is fully vested and exercisable.